Gastritis Treatment Guidelines

Introduction to Gastritis Treatment

The American Gastroenterological Association recommends PPIs as the first-line choice for most patients with gastritis, as they are more effective than H2-receptor antagonists, including famotidine, for treating esophageal GERD syndromes and gastric conditions 1

PPIs are more effective than H2-receptor antagonists, including famotidine, for treating esophageal GERD syndromes and gastric conditions, as recommended by the American Gastroenterological Association 1
For patients on dual antiplatelet therapy, famotidine is strongly preferred because it does not interfere with clopidogrel's antiplatelet activity, unlike PPIs, which can reduce clopidogrel effectiveness, as stated by the American Heart Association, similar to guidelines from Circulation 2

Famotidine may be preferred for short-term symptom relief, as it provides approximately 6 hours of acid suppression and can be effective for acute symptom management, according to the American Gastroenterological Association 4
When avoiding drug interactions is critical, famotidine does not interact with the cytochrome P-450 system, making it safer for patients on multiple medications, as recommended by the American Gastroenterological Association 3

Both famotidine and all H2 receptor antagonists develop tachyphylaxis within 6 weeks of treatment initiation, which limits their effectiveness for long-term use, as stated by the American Gastroenterological Association 3
Standard doses of H2 receptor antagonists, including famotidine, reduce duodenal but not gastric ulcers in NSAID users, according to the American Gastroenterological Association and Alimentary Pharmacology and Therapeutics 5

If a patient is on aspirin plus clopidogrel, choose famotidine 20 mg twice daily, as recommended by the American Heart Association, similar to guidelines from Circulation 2
If long-term therapy is anticipated, choose a PPI to avoid tachyphylaxis, as recommended by the American Gastroenterological Association 3

Do not use standard-dose famotidine for NSAID-related gastric ulcer prevention, as it is ineffective for gastric ulcers at standard doses, according to Alimentary Pharmacology and Therapeutics and the American Gastroenterological Association 5
Do not continue H2 antagonists beyond 6 weeks without reassessing efficacy due to tachyphylaxis development, as stated by the American Gastroenterological Association 3
Do not use PPIs in patients on clopidogrel without considering famotidine as an alternative, as PPIs can reduce clopidogrel's antiplatelet effects, as recommended by the American Heart Association, similar to guidelines from Circulation 2